BIOPHYTIS (EPA:ALBPS) - Biophytis shares and BSA trading is suspended pending a new press release
Transparency directive : regulatory news
07/05/2020 19:30
Click here to download pdf version
Press ReleaseBiophytis shares and BSA trading is suspended pending a new
press release
Paris (France), Cambridge (Massachusetts, USA), May 7, 2020, 7:30 p.m. CEST -
BIOPHYTIS (Euronext Growth Paris) asked Euronext Paris to suspend the trading
of its shares (ISIN code : FR0012816825-ALBPS) and BSA (ISIN code :
FR0013507290-BPSBS) as from today the 7th of May 2020, pending the publication
of a new press release.
****
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, especially
neuromuscular diseases.
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of BIO101 is being
developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company
plans to start the clinical development in H2 2020.
Sarconeos (BIO101) will also be developed as a treatment for Covid-19
(Coronavirus) for which the company has filed a clinical trial application with
the French Regulatory Authority (ANSM).
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO e
velyne.nguyen@biophytis.com
Media contact
Citigate Dewe Rogerson
Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart
biophytis@citigatedewerogerson.com
Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35
BIOPHYTIS's latest news
24/04/2024 23:00
24/04/2024 23:00
19/04/2024 07:00
19/04/2024 07:00
18/04/2024 07:02
18/04/2024 07:00
15/04/2024 07:00
08/04/2024 23:12
08/04/2024 23:10
08/04/2024 23:04
Other stories
25/04/2024 20:31
25/04/2024 20:23
25/04/2024 23:14
25/04/2024 18:05
25/04/2024 14:39
25/04/2024 20:19
25/04/2024 20:31
25/04/2024 22:31
25/04/2024 18:27
25/04/2024 16:56
25/04/2024 18:42
25/04/2024 22:15
25/04/2024 12:21
25/04/2024 09:11
25/04/2024 18:59
25/04/2024 17:29
25/04/2024 12:17
25/04/2024 14:05
25/04/2024 19:19
24/04/2024 12:30
24/04/2024 09:00
25/04/2024 08:13
25/04/2024 20:24
25/04/2024 21:54
25/04/2024 15:29
25/04/2024 17:19
25/04/2024 22:06
25/04/2024 23:16
25/04/2024 15:10
25/04/2024 18:54
25/04/2024 14:18
25/04/2024 19:30
25/04/2024 21:00
24/04/2024 19:06
25/04/2024 06:00
25/04/2024 17:23
Doctor shares red flag symptoms for silent killer cancer that is often mistaken for IBS - The Mirror
24/04/2024 22:01
25/04/2024 18:42